Hidradenitis Suppurativa Market: Increase in the Incidence of Chronic Inflammatory Skin Diseases to Drive the Market

Hidradenitis suppurativa is a dermatological disease that affects areas of apocrine sweat glands such as buttocks, area under the breast, under the arms, inner the thighs. It is also known as acne inversa. The disease is characterized by development of follicular occlusions that lead to progressive scarring. Early symptoms of hidradenitis suppurativa include erythema and local hidradenitis, which become painful in later stages. Hidradenitis suppurativa arises as a result of hormonal imbalance, friction from clothing, and sweating.

Read Report Overview - https://www.transparencymarketresearch.com/hidradenitis-suppurativa-market.html

According to an article published in Current Dermatology Reports in 2014; smoking, obesity, and genetic factors are also responsible for causing the disease. The disease is more prevalent in women as compared to men, with a ratio of 3:1. Globally, the disease affects around 1% of the population. The disease is uncommon but not rare. It can occur at any age, but it is most common at the age of 20–30 years.

Based on treatment, the global hidradenitis suppurativa market has been segmented into medications, laser treatment, surgery, and others. The medications segment has been sub-segmented into biologics, antibiotics, hormonal therapy, immunosuppressive drugs, zinc supplements, retinoids, pain medication, and others.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31538

Currently, only one FDA-approved therapeutic drug i.e. adalimumab (Humira) is available for treatment of hidradenitis suppurativa. Several antibiotics, hormone therapy, and corticosteroids are prescribed off-label. Treatment of hidradenitis suppurativa still remains a challenge for scientists worldwide. Surgical removal is also a preferred mode of treatment, but the disease may relapse in other areas. Research to develop drugs for the treatment of hidradenitis suppurativa is currently in progress.

As of 2017, certain drugs are under clinical development such as brilacidin, CJM 112, and xilonix. Increase in the incidence of chronic inflammatory skin diseases, the large number of ongoing clinical trials, and introduction to new treatment options are factors likely to boost the hidradenitis suppurativa market during the forecast period.

However, a weak pipeline has questioned growth of the market for hidradenitis suppurativa, as most of these trials are in phase II, indicating lesser chances of approval. This factor is projected to restrain the hidradenitis suppurativa market in the near future. In addition, high cost of therapy and associated side-effects are estimated to restrain the hidradenitis suppurativa market during the forecast period.

Request for Analysis of COVID-19 Impact on Hidradenitis Suppurativa Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=31538

Based on skin conditions, the hidradenitis suppurativa market has been divided into pimples, boils, deep-acne, folliculitis, and others. The folliculitis segment has been sub-segmented into hot tub folliculitis (pseudomonas folliculitis), bacterial folliculitis, pityrosporum folliculitis, barber's itch (pseudofolliculitis barbae), and others. The deep-acne segment has been further divided into blackheads, cysts, and others. The boils segment has been sub-divided into pilondial cyst, carbuncle, cystic acne, and others.

In terms of geography, the global hidradenitis suppurativa market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the global hidradenitis suppurativa market, followed by Europe. Growth of the market in North America is attributable to increase in the number of inflammatory skin conditions and the large number of ongoing clinical trials.

Pre Book Hidradenitis Suppurativa Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=31538&ltype=S

Asia Pacific is an emerging market for hidradenitis suppurativa, due to increase in the prevalence of hidradenitis suppurativa in this region. Developing health care infrastructure and rising government expenditure on the health care industry are factors projected to boost the hidradenitis suppurativa market in Asia Pacific during the forecast period. However, factors such as low awareness among patients, high cost of therapy, and limited access to health care facilities restrain the hidradenitis suppurativa market in regions such as Middle East & Africa and Latin America.

Major players operating in the global hidradenitis suppurativa market include AbbVie Inc., AstraZeneca, Johnson & Johnson, Merck & Co., Inc., Allergan, Pfizer Inc., and GlaxoSmithKline plc.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

Back to news